Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
The Pulmonary Hypertension Association (PHA), in conjunction with leading pulmonary hypertension specialists, has announced the launch of an educational campaign to raise awareness of the association between pulmonary arterial hypertension (PAH) and stimulant use, particularly methamphetamine use.
A two year old in Britain has a rare condition that causes chronic high blood pressure and must take Viagra to stay alive.
Combination therapy of Prostacyclin, Sildenafil, and Bosentan helped a young male patient with severe portopulmonary hypertension improve enough to receive a liver transplant.
The National Institute for Clinical Excellence (NICE) has published on its website the preliminary recommendations of its Appraisal Committee on the use of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for the treatment of pulmonary hypertension in adults.
New perspectives on lung cancer screening, complications of sleep apnea, cystic fibrosis, and other key topics in pulmonary and critical care medicine are presented in the special January issue of The American Journal of Medical Sciences, published by the Southern Society for Clinical Investigation and Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, provider of leading healthcare content, context and consulting.
Ikaria Holdings, Inc., through its subsidiary INO Therapeutics LLC, announced today that it has received approval from Australia's regulatory body, the Therapeutic Goods Administration (TGA), for INOmax (nitric oxide) for inhalation.
Researchers at the University of Granada ( UGR ) from the Systemic Autoimmune Diseases Unit and the Cardiology Service of the Hospital Clínico San Cecilio in Granada have developed an innovative system which will help doctors make the earliest diagnosis of pulmonary hypertension possible, which is the main cause of death for patients suffering from scleroderma, a rare disease which affects approximately 1,200 out of every million people.
Heart surgeons at Johns Hopkins say people who need heart transplants can largely avoid transplant failure due to elevated blood pressure in their lungs with the help of proper drug treatment.
A team of researchers from Wake Forest University, the National Institutes of Health and other institutions has discovered a previously undetected chemical process within the oxygen-carrying molecule hemoglobin that could have far-reaching implications for the treatment of cardiovascular diseases.
An intravenous "blood thinner" widely used in patients with acute coronary syndromes and during coronary artery stent placement appears to be safe in patients with sickle cell disease and may have beneficial anti-inflammatory effects, a small study at the University of North Carolina at Chapel Hill School of Medicine has found.
Certain preparations taken to enhance athletic performance or stave off disease contain an anti-oxidant that could cause harm.
A nationwide study led by researchers at UCSF provides evidence that inhaled nitric oxide is safe and effective for the prevention of the most common type of long-term lung disease of very premature infants.
Venous thrombosis (VTE), the formation of blood clots in a vein, is a major health problem for hospitalized patients in the United States.
Researchers from Boston University School of Medicine (BUSM) and Boston University School of Public Health (BUSPH) have developed a method to estimate sickle cell disease severity and predict the risk of death in people with this disease.
Two research studies published in The New England Journal of Medicine found taking SSRIs (selective serotonin reuptake inhibitors), anti-depression drugs, during pregnancy did not significantly increase the overall risk for most birth defects.
Researchers at the University of Alberta have identified a "central command system" for pulmonary hypertension, a disease that currently has no cure and kills thousands each year.
Protected by its own nutrients and blood supply, a beating heart supported by an investigational organ preservation device was successfully transplanted into a 47-year-old man with congestive heart failure and pulmonary hypertension on Sunday, April 8.
BioMarin Pharmaceutical has announced that the first patient has initiated treatment in the Phase 2a clinical study of 6R-BH4 (sapropterin dihydrochloride) for the treatment of sickle cell disease (SCD).
Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States and Europe. Accelerated reviews are granted to potential medicines that, if approved, would represent significant improvements over current therapies.
African-American women have the highest mortality rate for idiopathic pulmonary arterial hypertension (IPAH), according to new research.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.